1. Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review
   Maria Røed Skårderud et al, 2017, Cancer Treatment Reviews CrossRef
2. A meta-analysis of safety and efficacy of regorafenib for refractory metastatic colorectal cancer
   Wu-Song Xue et al, 2018, Medicine CrossRef
3. Associations among regorafenib concentrations, severe adverse reactions, and ABCG2 and OATP1B1 polymorphisms
   Akimitsu Maeda et al, 2018, Cancer Chemother Pharmacol CrossRef
4. Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice
   Tanios Bekaii-Saab et al, 2018, Clinical Colorectal Cancer CrossRef
5. Oncologic Outcomes in Metastatic Colorectal Cancer with Regorafenib with FOLFIRI as a Third- or Fourth-Line Setting
   Cheng-Jen Ma et al, 2019, Translational Oncology CrossRef
6. Comparison of Standard Initial Dose and Reduced Initial Dose Regorafenib for Colorectal Cancer Patients: A Retrospective Cohort Study
   Masayuki Nakashima et al, 2019, Targ Oncol CrossRef
7. Meta-Analysis of Regorafenib-Associated Adverse Events and Their Management in Colorectal and Gastrointestinal Stromal Cancers
   Ganfeng Xie et al, 2019, Adv Ther CrossRef
8. Regorafenib
   , 2017, Reactions Weekly CrossRef
9. Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial
   Cheng-Jen Ma et al, 2019, Trials CrossRef
10. Incidence and risk of regorafenib-induced hepatotoxicity
    Bin Zhao et al, 2017, Oncotarget CrossRef
11. Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib
    Bin Zhao et al, 2017, Oncotarget CrossRef
12. Retrospective study of regorafenib and trifluridine/tipiracil efficacy as a third‑line or later chemotherapy regimen for refractory metastatic colorectal cancer
    Akira Tanaka et al, 2018, Oncol Lett CrossRef
13. Impact of sarcopenia in patients with advanced or recurrent colorectal cancer treated with regorafenib
    Yasushi Murachi et al, 2020, Int J Clin Oncol CrossRef
14. Practical considerations in the use of regorafenib in metastatic colorectal cancer
    Fotios Loupakis et al, 2020, Ther Adv Med Oncol CrossRef
15. Trifluridine/Tipiracil and Regorafenib in Patients with Metastatic Colorectal Cancer: A Retrospective Study at a Tertiary Oncology Center
    Anuj K. Patel et al, 2021, The Oncol CrossRef
16. Therapeutic Potential of Regorafenib in Cisplatin-Resistant Bladder Cancer with High Epithelial–Mesenchymal Transition and Stemness Properties
    Feng-Che Kuan et al, 2023, IJMS CrossRef
17. Appropriate dose of regorafenib based on body weight of colorectal cancer patients: a retrospective cohort study
    Masayuki Nakashima et al, 2023, BMC Cancer CrossRef